AAPL 171.24 +2.63 (+1.56%)MSFT 110.63 +1.88 (+1.73%)FB 146.64 +4.56 (+3.21%)ZNGA 3.8 +0.15 (+3.97%)NVDA 152.46 +4.29 (+2.89%)WBA 83.03 +1.21 (+1.48%)GOOG 1080.15 +28.57 (+2.72%)PIH 5 -0.12 (-2.34%)
AAPL 171.24 +2.63 (+1.56%)MSFT 110.63 +1.88 (+1.73%)FB 146.64 +4.56 (+3.21%)ZNGA 3.8 +0.15 (+3.97%)NVDA 152.46 +4.29 (+2.89%)WBA 83.03 +1.21 (+1.48%)GOOG 1080.15 +28.57 (+2.72%)PIH 5 -0.12 (-2.34%)

Balance Sheet ADRO Quote Aduro Biote

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 150 75 158
ShortTermInvest 265 272 168
Cash 416 347 326
AccountReceivab 5 1 1
Inventories 0 0 0
DeferredIncomeT 0 6 0
OtherCurrentAss 0 0 17
TotalCurrentAss 425 355 350
PPE 6 30 38
AccumulatedDepr -2 -4 -7
NetPPE 4 26 31
EquityAndOtherI 15 14 24
Goodwill 8 8 9
IntangibleAsset 29 28 31
OtherLTAssets 0 1 0
TotalNonCurrent 57 84 95
TotalAssets 482 439 445
ShortTermDebt 0 0 0
AccountsPayable 5 2 1
TaxesPayable 0 1 0
AccruedLiabilit 11 13 18
DeferredRevenue 15 15 15
OtherCurrentLia 0 0 7
TotalCurrentLia 31 31 41
Debt 0 0 0
DeferredTaxesLi 7 6 7
DeferredRevenue 178 163 148
OtherLTLiabilit 4 12 12
TotalNonCurrent 189 181 166
TotalLiabilitie 220 211 208
CommonStock 0 0 0
AdditionalPaidI 363 421 519
RetainedEarning -101 -192 -284
AccumulatedOthe 0 -2 2
TotalStockholde 262 227 237
TotalLiabilitie 482 439 445
Aduro Biotech Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Aduro Biotech Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.